This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Given Imaging Announces Data Confirming PillCam(R) SB Can Improve Management And Outcomes In Patients With Crohn's Disease

SAN DIEGO, Oct. 15, 2013 (GLOBE NEWSWIRE) -- Given Imaging (Nasdaq:GIVN), a world leader in specialty GI products and pioneer of capsule endoscopy, today announced new studies validating PillCam SB's role in improving care, management and outcomes for patients with known or suspected Crohn's disease. The studies were presented at the American College of Gastroenterology's Annual Scientific Meeting and Postgraduate Course (ACG), taking place October 11-16, 2013, at the San Diego Convention Center, San Diego, CA, where Given Imaging is exhibiting at booth #1200 throughout the conference.

"PillCam SB is one of the most important tools we have for detecting and monitoring small bowel diseases, such as Crohn's disease. Due to the evolving nature of Crohn's disease, it's crucial that we monitor mucosal healing, as well as disease progression, so that we are able to continually improve the targeting of our treatment regimens," said Neel K. Mann, M.D., Associate Director, Small Bowel Enteroscopy, Cedars-Sinai Medical Center. "The compelling new data being presented at this year's ACG meeting shows that PillCam SB can help us reclassify disease phenotype to create a more tailored and effective management plan for each patient."

Several ACG poster presentations highlighted the clinical benefit of PillCam SB in Crohn's patients as a safe and valuable tool in disease evaluation and management, including:

  • "Capsule Endoscopy (CE) Can Improve Outcomes in Crohn's Disease: An Evaluation of Pre- and Post-treatment CE," poster 426, presented by Neel K. Mann, M.D. and Simon K. Lo, M.D., Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, Calif. The aim of this retrospective study was to assess small bowel mucosal healing based on the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI, Dig Dis Sci (2008) 53:1933-27) after initiation or escalation of therapy. CE results led to an escalation of therapy or switching of biologic agents in 53.6% of patients. There was a statistically significant difference in the CECDAI between the pre- and post-treatment CE (p=0.0250.) The study's authors concluded that PillCam SB helped to re-classify disease phenotype in more than 60% of patients with suspected Crohn's disease or unclassified Inflammatory Bowel Disease, thereby potentially changing the management as well as the natural outcomes of small bowel Crohn's disease. More importantly, capsule endoscopy demonstrated mucosal healing in 70% patients, after assessment of therapy, positively changing disease outcome and achieving therapeutic goals in patients with non-stricturing phenotype Crohn's disease.  
  • "Clinical Impact of Capsule Endoscopy in Patients with Established Crohn's Disease," poster 1720 , presented by researchers at McGill University Health Center, Montreal, QC, Canada, examined the impact of PillCam SB on the management of patients with established Crohn's disease. The results of this retrospective cross-sectional study of patients with established Crohn's disease showed that as a result of PillCam SB findings, 67% of patients had a change in management, including escalation in therapy, referral for surgery, de-escalation of anti-inflammatory therapy or initiation of therapy for concomitant IBS.  Investigators concluded that PillCam SB, a safe and valuable tool in disease evaluation and management, had a significant impact on managing treatment options for patients with established Crohn's disease.  
  • To help assess the value of monitoring in therapeutic management for Crohn's disease, Given Imaging supported researchers from the University of Chicago, Chicago Ill. and Cedars Sinai Medical Center, Los Angeles, Calf. in a national survey of gastroenterologists.  An analysis of this survey was presented by Adam C. Stein, M.D. in poster 420 , "Mucosal Healing in Inflammatory Bowel Disease: A Nationwide Survey of Gastroenterologists' Current Practice Patterns" .  The survey was conducted among community and academic gastroenterologists to determine current practice patterns for both achieving and maintaining mucosal healing in Crohn's and Ulcerative Colitis.  Results showed that the majority of surveyed gastroenterologists agreed that mucosal healing is the primary management goal in patients with both Crohn's and Ulcerative Colitis, and 57.1% indicated they would perform periodic endoscopy for disease monitoring even after mucosal healing was achieved and the patient was asymptomatic, or to assess for post-operative recurrence in Crohn's disease after ileocectomy with primary anastomosis.

About Crohn's Disease

Crohn's disease is a chronic condition that causes inflammation in the lining of the small intestine wall and can affect any part of the digestive tract. Symptoms can include diarrhea, abdominal pain, weight loss and rectal bleeding. Other cases of Crohn's may affect one or more of the following: the colon only, the small bowel only (duodenum, jejunum and/or ileum), the stomach or esophagus. 1 Roughly 500,000 Americans suffer from Crohn's disease, and about 20% have a direct relative with some form of inflammatory bowel disease (IBD). 2 Crohn's disease affects men and women equally. The cause is unknown; but, the most popular theory is that the immune system is reacting to a virus or bacterium that causes inflammation. 3 Depending on the severity, treatment options include nutritional supplements, drugs and surgery. There is currently no cure for the disease. 4

About PillCam ® SB

The PillCam SB capsule is a minimally invasive procedure to visualize and monitor small bowel abnormalities associated with Crohn's disease, iron deficiency anemia (IDA) and obscure GI bleeding (OGIB). The PillCam measures 11 mm x 26 mm and weighs less than four grams. Now in its third generation, PillCam SB 3 contains an imaging device and light source and transmits images at a rate between two and six images per second. Initially cleared by the U.S. Food and Drug Administration in 2001, PillCam SB is an accurate, patient-friendly tool used in patients two years and older by physicians to visualize the small bowel. PillCam SB 3 builds on Given Imaging's unique expertise and collaborative efforts as an industry leader that includes more than 2 million uses of PillCam capsules in patients worldwide and more than 1,900 clinical studies.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs